Drug Information

Drug General Information
Drug ID
D0AY1I
Former ID
DIB015649
Drug Name
GSK-2315698
Synonyms
GSK-2315698A; Serum amyloid P depleter (iv, amyloidosis), GlaxoSmithKline
Drug Type
Antibody
Indication Amyloidosis [ICD9: 277.3; ICD10:E85] Phase 1 [524198]
Company
GlaxoSmithKline plc
Target and Pathway
Target(s) Serum amyloid P-component Target Info [531012], [544468]
Reactome Amyloid formation
WikiPathways Human Complement System
Amyloids
References
Ref 524198ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health.
Ref 531012PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010 Jun;23(5):305-15.
Ref 544468Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.